Cartalax is sold as a cartilage bioregulator, a short peptide that supposedly tells aging chondrocytes to behave like young ones again. Search the indexed literature for what backs that pitch and the paper trail collapses fast. There is one legitimate mechanism finding, and there is one sentence in a review, written by researchers who overlap with the compound’s own developing circle, asserting it has been given to human patients. No sample size sits behind that sentence. No study design. No independent lab has weighed in on any of it.
What the evidence covers
Cartalax is the commercial name for the AED tripeptide, part of a family of short synthetic peptide bioregulators to come out of a Russian research program built around a small circle of gerontology researchers.
The strongest verified finding comes from a 2023 paper by Myakisheva and colleagues on chondrocyte aging. They characterized the senescence-associated secretory phenotype (SASP) that forms in aging chondrocytes: rising p16, p21 and p53, rising pro-inflammatory cytokines TNF-alpha and IL-1alpha, and falling Sirt1. Treating chondrocytes with the AED peptide, alongside a comparator called the cartilage polypeptide complex, normalized that pattern [1].
6senescence markers reported normalized by the AED peptide (Cartalax) in chondrocyte experimentsPMID 37356100
That is a real, specific, citable result. It is also not a clinical trial. A cultured chondrocyte’s protein levels shifting in a dish is not the same claim as a person’s joint pain improving.
The human claim sits somewhere else entirely: a separate 2023 review, also written by Myakisheva and colleagues, states that the AED tripeptide has shown “high efficacy in animal models of OA” and describes “oral administration in patients with OA of older age groups” [2]. That is the entire human evidence base the indexed literature offers. A summary clause inside someone else’s review, with no trial name, no patient count, no comparator group, and no design attached to it.
Bottom line: the one sentence in the literature that puts Cartalax and human patients in the same breath names no study behind it. You cannot look it up, because it was never described well enough to find.
Cell-level results are not human results
Both papers are interventional at the level they were run at. Add the peptide to a chondrocyte culture, measure a marker, and you have tested a cause and an effect, inside a dish.
What that design cannot do is tell you whether the same peptide, injected or swallowed by a person, reaches cartilage tissue at a concentration high enough to do anything. A chondrocyte bathed directly in a peptide solution and a chondrocyte sitting inside a joint capsule, behind synovial fluid and a wall of cartilage matrix, face two different exposure problems. Nothing in this record addresses the second one.
The mechanism marketing gets wrong
Vendor pages selling Cartalax tell a specific, appealing story: exposure increases collagen type II and aggrecan gene expression by named percentages, and separately turns up SOX9, the transcription factor that drives chondrocytes to differentiate. Three separate search passes across Europe PMC and PubMed turned up nothing connecting Cartalax, or the AED peptide, to any of those three genes.
Key gap: the collagen and SOX9 numbers repeated across vendor pages do not trace to any indexed study. The senescence-marker finding above is real, and it is a different mechanism than the one being marketed.
That substitution matters more than it might seem, because marketing built on peptide bioregulators tends to launder cell-culture plausibility into a specific-sounding number, and specific numbers read as more rigorous than they are. A reader comparing the vendor claim to the actual paper trail is comparing a percentage nobody can source against a real, if narrow, senescence finding that says something else.
The same laundering shows up with GHK-Cu, where topical-trial data gets quietly repurposed to back injectable products the trials never tested. The mechanism differs in each case. The move, borrowing credibility from a real result to cover a claim the literature never made, doesn’t.
Dosing: not published for anyone
No concentration, exposure duration, or administration schedule for Cartalax survived verification against a citable source. That absence covers both ends. Nothing establishes what was used on cultured cells in the studies that do exist, and nothing establishes a dose, injection frequency, or duration for a human being.
The second gap is the one that matters if you are the one taking it. Every dose posted on a vendor page or a forum thread is a guess, because the dose-ranging study that would tell anyone what an effective or safe human dose looks like has not been run, let alone published.
Safety: reported by nobody, tested by nobody
No adverse event data. No published study reports tolerability or a safety profile for Cartalax in humans.
No regulatory review. Vendors selling Cartalax label it “not for human consumption,” the standard disclaimer that lets a research-chemical seller sidestep the manufacturing and safety oversight that applies to an actual drug.
No interaction data. Nobody has studied Cartalax alongside other bioregulator peptides or standard osteoarthritis medications, so interaction risk is simply unknown.
What already has trial data that Cartalax doesn’t
Structured resistance training, backed by decades of controlled human trials.
Intra-articular corticosteroid injection for osteoarthritis flares.
Hyaluronic acid injection, studied and debated in enough trials to have a real argument about effect size.
These options carry a documented effect, even a modest or contested one. Choosing an unstudied peptide with a two-paper literature over any of them trades that documented effect for a research-chemical brand name. For a broader look at which peptide-marketing claims do have trial support behind them, see Natural Peptides: Which Claims Have Human Trials.
What would change this picture
A registered human trial, run outside the small circle of researchers who currently write about this compound, measuring a real cartilage or pain outcome, would be the first result that moves Cartalax past cell culture. Until one exists, “cartilage bioregulator” remains a marketing category here rather than a clinical one.
Verdict: Cartalax may eventually earn a place next to the interventions above, but it hasn’t yet, and buying it now is a bet that a two-paper literature, written by the people who developed it, will someday be replicated by someone with no stake in the answer.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
[Peptides prevent the forming of secretory phenotype of chondrocytes associated with the aging.].. Advances in gerontology = Uspekhi gerontologii, 2023.
[Chondrocytes secretory phenotype associated with aging: role in the pathogenesis of osteoarthritis and prospects for peptide bioregulation.].. Advances in gerontology = Uspekhi gerontologii, 2023.
